Data Sheet (Cat.No.T67822L)

TargetMol

Ulodesine

Chemical Properties



CAS No. :	548486-59-5
Formula:	C12H16N4O3
Molecular Weight:	264.28
Storage:	Powder: -20°C for 3 years | In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.

Biological Description

Description	Ulodesine (BCX4208) is a purine nucleoside phosphorylase (PNP) inhibitor that inhibits PNP with an IC50 value of 2.293 nM/L. Ulodesine may be used to study hyperuricaemia.
Targets(IC50)	Endogenous Metabolite
In vivo	Ulodesine intravenously effectively eradicates uric acid accumulations in the bloodstream of the mouse model.[1]

Solubility Information

Solubility	DMSO: 11 mg/mL (41.62 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (3.78 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.7839 mL	18.9193 mL	37.8387 mL
5 mM	0.7568 mL	3.7839 mL	7.5677 mL
10 mM	0.3784 mL	1.8919 mL	3.7839 mL
50 mM	0.0757 mL	0.3784 mL	0.7568 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Yang X, et al. Establishment of a novel hyperuricemiaanimal model using mice and assessment ofhyporuricemia action of PNP inhibitor Ulodesine. Chinese Pharmacological Bulletin, 2017: 883-886.
Diaz-Torné C, et al. New medications in development for the treatment of hyperuricemia of gout. Curr Opin Rheumatol. 2015;27(2):164-169.
Shahid H, et al. Investigational drugs for hyperuricemia. Expert Opin Investig Drugs. 2015;24(8):1013-1030.